Cargando…
Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data
BACKGROUND: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a catch-up campaign for children aged <5 years in Kilifi County. In a post-vaccination surveillance study based in Kilifi, there was a substantial decline in invasive pneumococcal disease (IPD). Howev...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571446/ https://www.ncbi.nlm.nih.gov/pubmed/28729018 http://dx.doi.org/10.1016/j.vaccine.2017.07.019 |
_version_ | 1783259339982635008 |
---|---|
author | Ojal, John Flasche, Stefan Hammitt, Laura L. Akech, Donald Kiti, Moses C. Kamau, Tatu Adetifa, Ifedayo Nurhonen, Markku Scott, J. Anthony G. Auranen, Kari |
author_facet | Ojal, John Flasche, Stefan Hammitt, Laura L. Akech, Donald Kiti, Moses C. Kamau, Tatu Adetifa, Ifedayo Nurhonen, Markku Scott, J. Anthony G. Auranen, Kari |
author_sort | Ojal, John |
collection | PubMed |
description | BACKGROUND: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a catch-up campaign for children aged <5 years in Kilifi County. In a post-vaccination surveillance study based in Kilifi, there was a substantial decline in invasive pneumococcal disease (IPD). However, given the continued circulation of the vaccine serotypes it is possible that vaccine-serotype disease may re-emerge once the effects of the catch-up campaign wear off. METHODS: We developed a compartmental, age-structured dynamic model of pneumococcal carriage and invasive disease for three serotype groups: the 10-valent vaccine serotypes and two groups of non-vaccine serotypes based on their susceptibility to mutual competition. The model was calibrated to age- and serotype-specific data on carriage and IPD in the pre-vaccination era and used to predict carriage prevalence and IPD up to ten years post-vaccination in Kilifi. The model was validated against the observed carriage prevalence after vaccine introduction. RESULTS: The model predicts a sustained reduction in vaccine-type pneumococcal carriage prevalence from 33% to 8% in infants and from 30% to 8% in 1–5 year olds over the 10-year period following vaccine introduction. The incidence of IPD is predicted to decline across all age groups resulting in an overall reduction of 56% in the population, corresponding to 10.4 cases per 100,000 per year. The vaccine-type IPD incidence is estimated to decline by 83% while non-vaccine-type IPD incidence is predicted to increase by 52%. The model's predictions of carriage prevalence agrees well with the observed data in the first five years post-vaccination. CONCLUSION: We predict a sustained and substantial decline in IPD through PCV vaccination and that the current regimen is insufficient to fully eliminate vaccine-serotype circulation in the model. We show that the observed impact is likely to be sustained despite waning effects of the catch-up campaign. |
format | Online Article Text |
id | pubmed-5571446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-55714462017-08-30 Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data Ojal, John Flasche, Stefan Hammitt, Laura L. Akech, Donald Kiti, Moses C. Kamau, Tatu Adetifa, Ifedayo Nurhonen, Markku Scott, J. Anthony G. Auranen, Kari Vaccine Article BACKGROUND: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a catch-up campaign for children aged <5 years in Kilifi County. In a post-vaccination surveillance study based in Kilifi, there was a substantial decline in invasive pneumococcal disease (IPD). However, given the continued circulation of the vaccine serotypes it is possible that vaccine-serotype disease may re-emerge once the effects of the catch-up campaign wear off. METHODS: We developed a compartmental, age-structured dynamic model of pneumococcal carriage and invasive disease for three serotype groups: the 10-valent vaccine serotypes and two groups of non-vaccine serotypes based on their susceptibility to mutual competition. The model was calibrated to age- and serotype-specific data on carriage and IPD in the pre-vaccination era and used to predict carriage prevalence and IPD up to ten years post-vaccination in Kilifi. The model was validated against the observed carriage prevalence after vaccine introduction. RESULTS: The model predicts a sustained reduction in vaccine-type pneumococcal carriage prevalence from 33% to 8% in infants and from 30% to 8% in 1–5 year olds over the 10-year period following vaccine introduction. The incidence of IPD is predicted to decline across all age groups resulting in an overall reduction of 56% in the population, corresponding to 10.4 cases per 100,000 per year. The vaccine-type IPD incidence is estimated to decline by 83% while non-vaccine-type IPD incidence is predicted to increase by 52%. The model's predictions of carriage prevalence agrees well with the observed data in the first five years post-vaccination. CONCLUSION: We predict a sustained and substantial decline in IPD through PCV vaccination and that the current regimen is insufficient to fully eliminate vaccine-serotype circulation in the model. We show that the observed impact is likely to be sustained despite waning effects of the catch-up campaign. Elsevier Science 2017-08-16 /pmc/articles/PMC5571446/ /pubmed/28729018 http://dx.doi.org/10.1016/j.vaccine.2017.07.019 Text en © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ojal, John Flasche, Stefan Hammitt, Laura L. Akech, Donald Kiti, Moses C. Kamau, Tatu Adetifa, Ifedayo Nurhonen, Markku Scott, J. Anthony G. Auranen, Kari Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data |
title | Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data |
title_full | Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data |
title_fullStr | Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data |
title_full_unstemmed | Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data |
title_short | Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data |
title_sort | sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in kilifi, kenya: a mathematical model based on pre-vaccination data |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571446/ https://www.ncbi.nlm.nih.gov/pubmed/28729018 http://dx.doi.org/10.1016/j.vaccine.2017.07.019 |
work_keys_str_mv | AT ojaljohn sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT flaschestefan sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT hammittlaural sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT akechdonald sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT kitimosesc sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT kamautatu sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT adetifaifedayo sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT nurhonenmarkku sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT scottjanthonyg sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata AT auranenkari sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata |